Related Experiment Video
Updated: Feb 17, 2026
07:29
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
9.8K
Novel polymorphisms associated with hyperalphalipoproteinemia and apparent cardioprotection
Connor P Oates1, Darya Koenig1, Jeffrey Rhyne1
1Division of Cardiovascular Medicine, Department of Medicine, University of Maryland School of Medicine and the Veterans Affairs Medical Center, Baltimore, MD, USA.
Journal of Clinical Lipidology
|December 5, 2017
Summary
Researchers identified novel genetic variants linked to high-density lipoprotein cholesterol (HDL-C) in individuals without coronary heart disease (CHD). These findings may offer new therapeutic targets for reducing CHD risk.
Area of Science:
- Genetics
- Cardiovascular Science
- Lipid Metabolism
Background:
- Hyperalphalipoproteinemia (HALP) is inversely correlated with coronary heart disease (CHD).
- Genetic variants linked to high serum levels of high-density lipoprotein cholesterol (HDL-C) have not been definitively proven cardioprotective.
- Understanding genetic underpinnings of HALP is crucial for cardiovascular risk assessment.
Purpose of the Study:
- To identify novel genetic variants associated with HALP.
- To explore potential links between these variants and reduced risk of CHD.
- To investigate the functional impact of identified genetic polymorphisms.
Main Methods:
- Analysis of exome sequencing data, HDL-C, and triglyceride levels in 1645 subjects from diverse cohorts.
- Identification of novel nonsynonymous single-nucleotide polymorphisms (nsSNPs) in individuals with primary HALP.
- Utilized PolyPhen-2 and Combined Annotation Dependent Depletion for predictive effect estimation of nsSNPs.
Main Results:
- Rare, deleterious polymorphisms were identified in genes including UGT1A3, PLLP, PLEKHH1, ANK2, DIS3L, ACACB, and LRP4 in subjects with HALP.
- A novel polymorphism, rs376849274, was found in OSBPL1A.
- These candidate genes are largely involved in lipid metabolism, and affected individuals lacked CHD history despite risk factors.
Conclusions:
- Novel functional polymorphisms in eight candidate genes are associated with HALP in the absence of CHD.
- These findings suggest potential genetic contributors to cardiovascular health in HALP individuals.
- Further research is warranted to explore these genes as therapeutic targets for CHD risk reduction.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
10
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
10
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
10
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
10
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
18
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
18
01:26Atherosclerosis III: Management
460
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
460
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
19
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
19
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
539
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
539